You’re Invited to Time to Target: Glycemic Innovation & Collaboration Summit

Hi, I'm John Downey, the Chief Commercial Officer at Glytec. 

Glytec helps clinicians personalize insulin dosing for the roughly 40% of hospitalized patients whose care would benefit from insulin therapy.

Earlier this month, CMS announced new quality metrics and reporting guidelines for glycemic management. It’s clear that CMS is attempting to make severe hypoglycemia related to insulin a never event. It’s also clear that hospitals should move to prioritize the optimal treatment and management of severe hyperglycemia.

I am inviting you to learn more about these new CMS measures at “Time to Target,” our conference on glycemic innovation and collaboration.

We believe that hospital leaders are hungry for actionable information to help prepare for more scrutiny on glycemic matters and we've gathered top industry experts, key opinion leaders and our own innovative partners to share thoughts on how to create and manage a sustainable best-in-class glycemic management program.

At Glytec, we've known the importance of optimal glycemic management since our founding in 2006. We’re currently partnered with more than 300 hospitals to provide the people, processes, and technology to help reduce rates of hypo and hyperglycemia.

Please join us for two half-day virtual programs taking place on October 26^th and 27^th.

We will feature panels and presentations on a wide array of topics relating to the current and future state of glycemic management in the hospital.

This virtual event is free and is designed to be modular so you can pick which sessions to attend.  

Please go to www.GlytecTimeToTarget.com for more information and complimentary registration.

Consistent, individualized, technology-driven glycemic management is no longer a nice to have, it is a must have. 

I hope to see you at Time to Target.